New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies

University Hospital, Strasbourg, France100 enrolled

Overview

BK virus (BKV) infection has a major negative impact on transplant recipients. No BKV-specific antiviral therapy is available, so there is an urgent need to develop new anti-BKV preventive and therapeutic strategies.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

BK Virus Infection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * BK positive * adult * ok to participed to research Exclusion Criteria: * under guardianship * under curatorship * opposed to research * deprived of liberty

Locations (1)

Service de Virologie - CHU Strasbourg - France

Strasbourg, France

RECRUITING

Outcomes

Primary Outcomes

Ability of the isolated monoclonal antibodies to neutralize all 3 BKV genotypes

The neutralization titer will be defined as the dilution of the sample that produced 50% inhibition of pseudovirion infectivity (IC50)

Time frame: 5 years

Central Contacts

Anne-Sophie U GEY

CONTACT

+33 388116684 anne-sophie.gey@chru-strasbourg.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.